Genascence Granted FDA Fast Track Designation for GNSC-001 in Patients With Osteoarthritis (OA) of the Knee
UF Startup Genascence Corporation announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) for GNSC-001, a potential first-in-class gene therapy for the treatment of patients with osteoarthritis (OA) of the knee.
Morphogenesis’ Skin Cancer Vaccine Gets FDA ‘Fast Track’
Tampa company Morphogenesis, a UF startup, has received a “fast track” designation for its skin cancer vaccination from the United States Food and Drug Administration.